You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1895 Results
Regimen
Cancer Type:
Breast, 
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Aug 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Oct 2023
Regimen
Intent: Palliative
Oct 2022
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Dec 2023
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Palliative
Oct 2022
Regimen
Intent: Palliative
Oct 2023
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • goserelin
Mar 2016
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
May 2020
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
May 2020
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Temsirolimus - Metastatic Renal Cell Carcinoma
Jun 2024
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    vanDETanib - Monotherapy for symptomatic and/or progressive medullary thyroid cancer (MTC), with specific criteria
Nov 2023

Pages